4Siderowf A,Stern M.Update on Parkinson disease[J].Ann Inter n Med,2003,138(8):651.
5Hardy J,Langston JW.How many pathways are there to nigral death[J] Ann Neurol,2004,56:316-318.
6Schwarz J.Rationale for dopamine agonist use as monotherapy in Parkinson's disease[J].Curr Opin Neurol,2003,16(1):S27-33.
7Moresco RM,Volonte MA,Messa C,et a1.New perspectives on neuroehemieal effects of arnantadine in the brain of parkinsonian patients:a PET-[(11)] C raclopride study[J].J NeuralTransm,2002,1O9(10):1265-1274.
8Eric P,Kindw all,Harr y T.whelan.实用高压氧医学[M].西安第四军医大学出版社,2004.39-44.
10Riaz SS,Bradford HF.Factors involved in the determination of the neurotransmitter phenotype of developing neurons of the CNS:applications in cell replacement treatment for Parkinson's disease[J].ProgNeurobiol 2005,76(4):257-278.